Last updated on April 2020

GAIN Trial – Alzheimer’s Disease Research Study mild to moderate


Brief description of study

The Memory Health Center at Summit Research Network, is enrolling participants in the GAIN clinical trial.  This trial will evaluate whether the investigational medication, COR388, is safe and can slow or stop the progression of Alzheimer’s by reducing the damage caused by a bacteria commonly associated with gum disease that can travel to the brain.

 

Detailed Study Description

  • Study participation will last about a year.  
  • Following a screening period of up to 6 weeks, qualified participants will be randomly assigned to the oral investigational medication, C0R388, or a placebo (an inactive substance).  
  • During the treatment period, the participants will visit the research center 9 times over a 48 week period.  
  • All participants will come back 6 weeks after the final study visit for a follow-up visit.

 

Clinical Study Identifier: TX226200

Find a site near you

Start Over

Summit Research Network, Inc.

2701 NW Vaughn Street, Suite 350 Portland, OR USA
  Connect »